Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Starlix/Diovan Combo Trial In Diabetes Planned For Fourth Quarter

Executive Summary

Novartis hopes to begin a study of Starlix and Diovan used in combination for the prevention of type 2 diabetes before year-end.

You may also be interested in...



Novartis Expects Zelnorm U.S. Approval Despite EU Filing Withdrawal

Novartis continues to expect U.S. approval of Zelnorm (tegaserod) despite problems with the marketing application for the irritable bowel syndrome therapy in Europe.

Novartis Lotensin

Professional Detailing, Inc. gains U.S. marketing rights for the ACE inhibitor benazepril and Lotensin HCT (benazepril/hydrochlorothiazide) through 2003. PDI will also co-promote Lotrel (amlodipine/benazepril). Novartis will continue to manufacture the three products

Novartis Gleevec For Leukemia Will Be In Pharmacies By Mid-May

Novartis' chronic myeloid leukemia therapy Gleevec will be available in pharmacies by the time oncologists return from the American Society of Clinical Oncology May 12-15 meeting.

Related Content

UsernamePublicRestriction

Register

PS037999

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel